The company has developed technology for production and purification to injection-grade hSA in the lab scale. A pilot plant for production will now be established at Shanghai’s Zhangjiang Center for Biomedicine Development.
Science Daily, Oct. 15, 2012
HaiXin Rhett Biomedical Technology Co., Shanghai, starts pilot-scale production of recombinant human serum albumen in Shanghai